Market's view on Proteome
Published on April 2024
- Proteome Sciences is observed to have a positive movement in its share price, breaking an eight-month downtrend, which is attributed to hints of upcoming significant contracts.
- A Stock watcher comments on the overall failure of the company to significantly impact shareholders positively despite being in business for 30 years, criticising the management for only covering operational costs.
- Doubts are expressed concerning the management’s capability, with comparisons made to larger industry failures.
- Frustration is shown towards a recent announcement by the company about a £500,000 deal, described by some as too minor to be significant.
- Optimism is shared regarding Proteome Sciences’ first contract in America, using their facilities there, which is seen as a vital move that justifies their expansion and could potentially attract more contracts.
- Concerns are mentioned about the company’s historical performance, implying a lack of satisfactory returns to shareholders over a long period.
- Some watchers show support and optimism, highlighting recent wins as a starting point for potential future success and higher share prices.
- The company’s involvement in significant areas such as Alzheimer’s disease, cancer, and stroke through their intellectual property is identified as potential for substantial future valuation increases.
- Criticism is directed at the executive’s perceived complacency with merely sustaining the company rather than achieving substantial growth or returns.